CTLA4 and neoplasm: Prior studies have noted that patients responding to anti–PD-1 (with or without anti–CTLA-4) therapy have higher baseline TCR clonality in the tumor microenvironment (24) and harbor large clones that gain more DEGs during therapy than do nonresponding patients (23).